REVEAL-GENOMICS-S.L.
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509117263/en/
The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.
If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.
In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint. HER2DX® pCR-score and HER2DX® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.
The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."
Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.
REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."
HER2DX® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine
The inclusion of HER2DX® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.
This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.
About HER2DX®️
HER2DX®️ is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS®️ since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
HER2DX®️ is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.
HER2DX®️ predicts:
- Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
- pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
- ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.
About ECOG-ACRIN
ECOG-ACRIN is renowned for advancing precision medicine and biomarker research through its leadership of major clinical trials that integrate cutting-edge genomic approaches. Through the CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial Program, ECOG-ACRIN is collaborating with the Alliance for Clinical Trials in Oncology to investigate the optimization of therapy in patients with HER2+ breast cancer. The CompassHER2 pCR Trial (NCT04266249) was the first to open in this program, funded by the National Cancer Institute, part of the US National Institutes of Health.
Web: www.ecog-acrin.org, X: @eaonc. Other: Facebook, LinkedIn, and Instagram.
About REVEAL GENOMICS®️
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.
REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d’Hebron Institute of Oncology (VHIO).
REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.
Web: www.reveal-genomics.com. X: @revealgenomics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509117263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mesmerise to collaborate with Mayo Clinic to Transform Medical Education and Healthcare Workforce Training13.1.2025 23:10:00 CET | Press release
Mesmerise is proud to announce the creation of NeuRealities, Inc., a transformative company designed to revolutionize medical education and healthcare training. As part of a know-how agreement with Mayo Clinic, the new company seeks to leverage Mayo Clinic’s unparalleled clinical expertise and trusted knowledge with Mesmerise’s pioneering advancements in AI-powered spatial computing to set a new standard for excellence in immersive learning experiences. NeuRealities aims to introduce an open-standards digital platform that redefines how healthcare professionals learn and train. By integrating hyper-realistic AI-enabled digital humans, adaptive immersive experiences, and dynamic content tailored to individual learners, the platform can address critical gaps in medical education. Its first initiative—CT training for radiologic technicians—delivers interactive, hands-on scenarios that simplify complex medical concepts, allowing the potential for training to be more efficient, accessible,
Jefferies to Hold Global Trading Day on January 16 to Support Los Angeles Wildfire Relief Efforts13.1.2025 22:15:00 CET | Press release
Jefferies announced today that it will hold a Global Trading Day on January 16, 2025, to raise funds for organizations supporting first responders and those impacted by the fires. Jefferies will donate 100% of net global commissions on January 16 for all trading in equities and fixed income by the Firm’s clients. Jefferies will also make a $1 million donation and encourage its nearly 6,000 employees to personally support relief efforts. During the month following this Global Trading Day, contributions will be carefully allocated to qualified charities to ensure the proceeds go directly to support the people and communities most in need. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are heartbroken by the wildfires causing unfathomable destruction in the Los Angeles area. Our firm was founded in Los Angeles 62 years ago, and it has always been a resilient community, full of dynamism, opportunity and strength. Our hearts go out to all those affected, and we sta
AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring13.1.2025 16:00:00 CET | Press release
AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO). Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks. Key Benefits of the WMO-Compliant AWSPrecision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications. Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting. Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demanding
Greenland Resources Signs Advisory Agreement With Rasmussen Global on Defense13.1.2025 15:30:00 CET | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) “Greenland Resources” or the “Company”) is pleased to announce that it has signed an advisory agreement with Rasmussen Global to complement the Malmbjerg Project existing funding strategy through potential strategic supranational partners, including the North Atlantic Treaty Organization (NATO) Innovation Fund and the European Defense Fund. Rasmussen Global was founded and is chaired by Anders Fogh Rasmussen, the former Prime Minister of Denmark and former Secretary General of NATO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113410398/en/ The Project is strategically located in east central Greenland and based on its current NI 43-101 Feasibility Study, can supply some 25% of the European Union (EU) total molybdenum consumption for decades to come including nearly all the EU defense needs. Currently, the EU is the 2nd largest molybdenum user in the world and has no
Starr Names Peter Hirs to Succeed Howard Smith as CFO13.1.2025 15:30:00 CET | Press release
Starr announced that Peter Hirs has been named the company’s chief financial officer, effective January 13, succeeding Howard I. Smith, who is retiring after more than 40 years at Starr and related entities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113071409/en/ Peter Hirs, chief financial officer, Starr (Photo: Business Wire) Hirs brings significant finance and insurance experience to Starr, having spent the past 20 years at a global insurance carrier, where he managed regional finance teams across the world and led mergers and acquisitions activities. In his new role, Hirs will oversee the organization’s global finance operations. He is based at Starr’s head office in New York. Smith had led Starr’s financial operations since 2005, when Maurice R. “Hank” Greenberg, Starr’s chairman emeritus, re-established Starr as a free-standing investment and insurance organization, and he worked closely with Hank prior to that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom